{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["5(5)"],"submitter":["Hanessian S"],"pubmed_abstract":["In connection with a program directed at potent and balanced dual NK1/NK3 receptor ligands, a focused exploration of an original class of peptidomimetic derivatives was performed. The rational design and molecular hybridization of a novel phenylalanine core series was achieved to maximize the in vitro affinity and antagonism at both human NK1 and NK3 receptors. This study led to the identification of a new potent dual NK1/NK3 antagonist with pK i values of 8.6 and 8.1, respectively."],"journal":["ACS medicinal chemistry letters"],"pagination":["550-5"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4027792"],"repository":["biostudies-literature"],"pubmed_title":["Design, Synthesis, and Optimization of Balanced Dual NK1/NK3 Receptor Antagonists."],"pmcid":["PMC4027792"],"pubmed_authors":["Millan MJ","Soma U","Mannoury la Cour C","Hanessian S","Boyer N","De Nanteuil G","Babonneau V","Jennequin T"],"additional_accession":[]},"is_claimable":false,"name":"Design, Synthesis, and Optimization of Balanced Dual NK1/NK3 Receptor Antagonists.","description":"In connection with a program directed at potent and balanced dual NK1/NK3 receptor ligands, a focused exploration of an original class of peptidomimetic derivatives was performed. The rational design and molecular hybridization of a novel phenylalanine core series was achieved to maximize the in vitro affinity and antagonism at both human NK1 and NK3 receptors. This study led to the identification of a new potent dual NK1/NK3 antagonist with pK i values of 8.6 and 8.1, respectively.","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 May","modification":"2025-04-22T17:42:50.139Z","creation":"2019-03-27T01:28:35Z"},"accession":"S-EPMC4027792","cross_references":{"pubmed":["24900878"],"doi":["10.1021/ml400528y"]}}